Medical decision analysis for first-line therapy of chronic myeloid leukemia

References

• Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007;370:342–350.
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Gugliotta G, et al. Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a “head-to-head comparison”. Leuk Lymphoma 2010;51: 583–591.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration [Internet]. 2003. Available from: http://wwwaccessdatafdagov/scripts/cder/ob/docs/obdetailcfm?Appl_No = 021588&TABLE1 = OB_Rx
   Google Scholar
• European Medicines Agency [Internet]. 2001. Available from: http://wwwemaeuropaeu/ema/indexjsp?curl = pages%2Fmedicines%2Flanding%2Fepar_searchjsp&mid=WC0b01ac058001d124&search Tab = &already Loaded = true&isNewQuery = true&status= Authorised&status=Withdrawn&status =Suspended & status=Refused&start Letter=G&keyword=Enter+ keywords&searchType=name& taxonomyPath= &treeNumber= &searchGenericType= generics
   Google Scholar
• Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–1820.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes JE, Giles FJ, et al. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007;109: 2171–2181.
   PubMed Web of Science ®Google Scholar
• Deininger M, O’Brien S, Guilhot F, et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114(Suppl. 1): Abstract 1126.
   Google Scholar
• Kantarjian H, O’Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007;109:1556–1560.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531–2541.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–2259.
   PubMed Web of Science ®Google Scholar
• Hunink MGM, Glasziou PP, Siegel JE, et al. Decision making in health and medicine: integrating evidence and values. Cambridge, UK: Cambridge University Press; 2001.
   Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al.; ISPOR-SMDM Modeling Good Research Practices Task Force.Modeling good research practices-- overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health 2012;15:796–803.
   PubMed Web of Science ®Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Med Decis Making 2012;32:690–700.
   PubMed Web of Science ®Google Scholar
• Statistik Austria [Internet]. Jährliche Sterbetafeln seit 1947 für Österreich [Annual mortality tables since 1947 for Austria]. Austria. 2012. Available from: http://wwwstatistikat/web_de/statistiken/bevoelkerung/demographische_masszahlen/sterbetafeln/indexhtml
   Google Scholar
• Hoyle M, Pavey T, Ciani O, et al. Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. 1st-line TKIs for chronic CML: final NICE report. Technology Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Clinical Excellence. Exeter, UK: Peninsula Technology Assessment Group (PenTAG), University of Exeter; 2011.
   Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054–1061.
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon versus STI571 (IRIS) 7-Year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood 2008;112(Suppl. 1):Abstract 186.
   Google Scholar
• Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204–3212.
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232–240.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540–3546.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Bhalla K, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008;112(Suppl. 1):Abstract 3238.
   Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141–1145.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Lopez-Guillermo A, Bosch F, et al. An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol 1996;57:286–291.
   PubMed Web of Science ®Google Scholar
• Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004;101:2574–2583.
   PubMed Web of Science ®Google Scholar
• Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010;115:1880–1885.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Brand R, Apperley J, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002;100:3877–3886.
   PubMed Web of Science ®Google Scholar
• Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010;26:183–191.
   PubMed Web of Science ®Google Scholar
• Dalziel K, Round A, Garside R, et al. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005;23:515–526.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang C, Xu X, et al. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). Value Health 2009;12(Suppl. 3):S85–S88.
   Google Scholar
• Quintas-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908–3914.
   PubMed Web of Science ®Google Scholar
• Stephens J, Carpiuc KT, Botteman M. The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis. Int J Gen Med 2010;3:31–36.
   PubMedGoogle Scholar
• Lee SJ, Kuntz KM, Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med 1997;127:1080–1088.
   PubMed Web of Science ®Google Scholar
• Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. Value Health 2012;15:843–850.
   PubMed Web of Science ®Google Scholar
• Statistik Austria [Internet]. Jährliche Sterbetafeln seit 1947 für Österreich [Annual mortality tables since 1947 for Austria]. Austria. 2013. Available from: http://wwwstatistikat/web_de/static/jaehrliche_sterbetafeln_1947_bis_2012__fuer_oesterreich_022707pdf
   Google Scholar
• Garrison LP Jr, Wang ST, Huang H, et al. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist 2013;18:27–36.
   PubMed Web of Science ®Google Scholar
• Rochau U, Schwarzer R, Sroczynski G. Overview and evaluation of decision-analytic models in the treatment of CML. Poster presented at 33rd Annual Meeting of the Society for Medical Decision Making (SMDM), 22–26 October 2011, Chicago, IL, USA.
   Google Scholar
• National Institute for Health and Clinical Excellence. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance. NICE technology appraisal guidance 241. London, UK: NICE; 2012.
   Google Scholar
• Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with chronic myeloid leukemia (CML), resistant to standard dose imatinib--a Swedish model application. Acta Oncol 2010;49:851–858.
   PubMed Web of Science ®Google Scholar
• Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care?Eur J Health Econ 2003; 4:143–150.
   Google Scholar
• Siebert U, Sroczynski G, Zietemann V. Pharmacogenomics bias - systematic distortion of study results by genetic heterogeneity. GMS Health Technol Assess 2008;4:Doc03.
   Google Scholar